Investigational drug · Phase 3
Pamiparib
Also called: BGB-290
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ovarian Cancer, Advanced Malignancies.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
36
Any phase or sponsor naming "Pamiparib"
First trial start
2018
May 14, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pamiparib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ovarian Cancer
- Advanced Malignancies
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Pamiparib" as an intervention, largest first.
University Hospital, CaenAcademic, hospital or other
NCT04774406 · 2,336 participants · Start Feb 24, 2021 · Primary completion May 9, 2021
Drug: olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib · For: Cancer
Sites: Caen, France
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
NCT05406999 · 900 participants (planned) · Start Feb 1, 2020 · Primary completion Dec 31, 2026
Drug: ADT; Abiraterone Acetate and 6 more · For: Neoadjuvant Therapy; High Risk Prostate Cancer; Locally Advanced Prostate Cancer and 1 more
Sites: Nanjing, China
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesPivotal-lookingCompleted
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04164199 · 404 participants · Start Dec 19, 2019 · Primary completion May 23, 2026
Drug: Tislelizumab; Pamiparib and 11 more · For: Advanced Malignancies
Sites: Miami, Florida; New York, New York; Nashville, Tennessee · 106 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT02660034 · 229 participants · Start Feb 2, 2016 · Primary completion Sep 9, 2020
Drug: Tislelizumab; Pamiparib · For: Solid Tumors
Sites: Scottsdale, Arizona; Los Angeles, California; Denver, Colorado · 29 sites in all
- Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian CancerPivotal-lookingActive, not recruiting
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03519230 · 224 participants · Start May 14, 2018 · Primary completion Dec 1, 2025
Drug: Pamiparib capsule; Placebo capsule · For: Ovarian Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 28 sites in all
Peking University Shenzhen HospitalAcademic, hospital or other
NCT06692491 · 200 participants (planned) · Start Jan 1, 2025 · Primary completion Dec 31, 2027
Drug: Albumin-Bound Paclitaxel; Epirubicin and 26 more · For: Rare Tumour
University Hospital, CaenAcademic, hospital or other
NCT04774627 · 200 participants · Start Feb 7, 2021 · Primary completion Feb 27, 2021
Drug: PARP inhibitor · For: Cancer
Sites: Caen, France
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03150810 · 139 participants · Start Jun 28, 2017 · Primary completion May 4, 2023
Drug: Pamiparib; Temozolomide · For: Locally Advanced or Metastatic Solid Tumors
Sites: Grand Rapids, Michigan; St Louis, Missouri; New York, New York · 22 sites in all
- Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03427814 · 136 participants · Start Jul 3, 2018 · Primary completion Jun 18, 2020
Drug: Pamiparib; Placebo · For: Advanced or Inoperable Gastric Cancer
Sites: Miami, Florida; West Palm Beach, Florida; Goshen, Indiana · 65 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03333915 · 128 participants · Start Dec 21, 2016 · Primary completion Aug 24, 2020
Drug: Pamiparib · For: Advanced High-grade Ovarian Cancer; Triple Negative Breast Cancer
Sites: Beijing, China; Zhengzhou, China; Changsha, China · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- [18F]Pamiparib: Synthesis and evaluation of a novel PARP1/2 radiotracer in rodent and nonhuman primate brain.
Tong J, Hernandez-Martin N, Balayeva T, et al. · Nucl Med Biol 2026
- Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study.
Gong T, Liang S, Wu Z, et al. · Prostate Cancer Prostatic Dis 2026
- Pamiparib plus surufatinib with ctDNA monitoring in platinum-resistant ovarian cancer after PARP inhibitor progression: a phase Ib/II trial (POST-PARPi).
Fang C, Liang H, Shen X, et al. · BMC Med 2026
- Safety and tolerability of PARP inhibitors in cancer patients: a network meta-analysis of randomized controlled trials.
Wei C, Liu S, Hu J, et al. · BMC Cancer 2026
- Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).
Ellingson BM, Cloughesy TF, Ye X, et al. · AJNR Am J Neuroradiol 2026
- Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors.
Rani D, Plebanski M, Chatterjee T · RSC Adv 2026
Also in development for Ovarian Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.